Soluble guanylyl cyclase: Physiological role as an NO receptor and the potential molecular target for therapeutic application

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 7, 2003, Pages 865-870

  Nakane, Masaki ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Cardiovascular; Erectile dysfunction; Nitric oxide; Soluble guanylyl cyclase; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; A 344905; CYCLIC GMP; ENZYME ACTIVATOR; GUANYLATE CYCLASE; HEME; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANTICOAGULATION; BIOSYNTHESIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; HISTOLOGY; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; SURVIVAL; THROMBOCYTE; VASODILATATION;

ANIMALS; BINDING SITES; CLONING, MOLECULAR; GUANYLATE CYCLASE; HUMANS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PROTEIN SUBUNITS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT PROTEINS;

EID: 0042975272     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.131     Document Type: Review

References (49)

1. Murad F. The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate. J Am Med Assoc 1996; 276:1189-92.
2. Davis KL, Martin E, Turko IV, Murad F. Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol 2001; 41:203-36.
3. Bult H, Herman AG, Matthys KE. Antiatherosclerotic activity of drugs in relation to nitric oxide function. Eur J Pharmacol 1999; 375:157-76.
4. Janero DR. Nitric oxide (NO)-related pharmaceuticals: contemporary approaches to therapeutic NO modulation. Free Radic Biol Med 2000; 28:1495-506.
5. Moreland RB, Hsieh G, Nakane M, Brioni JD. The biochemical and neurologic basis for the treatment of male erectile dysfunction. J Pharmacol Exp Ther 2001; 296:225-34.
6. Brioni JD, Nakane M, Hsieh GC, Moreland RB, Kolasa T, Sullivan JR, Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res 2002; 14:8-14.
7. Viner RI, Ferrington DA, WilliamsTD, Bigelow DJ, Schoneich C. Protein modification during biological aging: selective tyrosine nitration of the SERCA2a isoform of the sarcoplasmic reticulum Ca2+-ATPase in skeletal muscle. Biochem J 1999; 340:657-69.
8. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxidesensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3- alquinoxalin-1-one. Mol Pharmacol 1995; 48:184-8.
9. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-alquinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 1996; 50:1-5.
10. Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 1995; 116:1973-8.
11. . Friebe A, Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 1998; 53:123-7.
12. Stone JR, Marletta MA. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chem Biol 1998; 5:255-61.
13. Denninger JW, Schelvis JP, Brandish PE, Zhao Y, Babcock GT, Marietta MA. Interaction of soluble guanylate cyclase with YC-1: kinetic and resonance Raman studies. Biochemistry 2000; 39:4191-8.
14. Margulis A, Sitaramayya A. Rate of deactivation of nitric oxide-stimulated soluble guanylate cyclase: influence of nitric oxide scavengers and calcium. Biochemistry 2000; 39:1034-9.
15. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001; 410:212-5.
16. Becker EM, Alonso-Alija C, Apeler H, Gerzer R, Minuth T, Pleibeta U, et al. NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BIVIC Pharmacol 2001; 1:13.
17. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz J, Ducke B, Feurer A, et al. NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 2001; 11:781-4.
18. Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 2002; 135:344-55.
19. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, et al. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 2002; 135:333-43.
20. Kamisaki Y, Waldman SA, Murad F. The involvement of catalytic site thiol groups in the activation of soluble guanylate cyclase by sodium nitroprusside. Arch Biochem Biophys 1986; 251:709-14.
21. Nakane M, Saheki S, Kuno T, Ishii K, Murad F. Molecular cloning of a cDNA coding for 70 kilodalton subunit of soluble guanylate cyclase from rat lung. Biochem Biophys Res Commun 1988; 157:1139-47.
22. Nakane M, Arai K, Saheki S, Kuno T, Buechler W, Murad F. Molecular cloning and expression of cDNAs coding for soluble guanylate cyclase from rat lung. J Biol Chem 1990; 265:16841-5.
23. Yuen PS, Potter LR, Garbers DL. A new form of guanylyl cyclase is preferentially expressed in rat kidney. Biochemistry 1990; 29:10872-8.
24. Gupta G, Azam M, Yang L, Danziger RS. The beta2 subunit inhibits stimulation of the alphal/betal form of soluble guanylyl cyclase by nitric oxide. Potential relevance to regulation of blood pressure. J Clin Invest 1997; 100:1488-92.
25. Harteneck C, Wedel B, Koesling D, Malkewitz J, Bohme E, Schultz G. Molecular cloning and expression of a new alpha-subunit of soluble guanylyl cyclase. Interchangeability of the alpha-subunits of the enzyme. FEBS Lett 1991; 292:217-22.
26. Giuili G, Scholl U, Buile F, Guellaen G. Molecular cloning of the cDNAs coding for the two subunits of soluble guanylyl cyclase from human brain. FEBS Lett 1992; 304:83-8.
27. Zabel U, Weeger M, La M, Schmidt HH. Human soluble guanylate cyclase: functional expression and revised isoenzyme family. Biochem J 1998; 335:51-7.
28. Behrends S, Vehse K. The beta(2) subunit of soluble guanylyl cyclase contains a human-specific frameshift and is expressed in gastric carcinoma. Biochem Biophys Res Commun 2000; 271:64-9.
29. Nakane M, Hsieh G, Miller LN, Chang R, Terranova MA, Moreland RB, et al. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. J Urol 2001; 165:223.
30. Denninger JW, Marietta MA. Guanylate cyclase and the .NO/cGMP signaling pathway. Biochim Biophys Acta 1999; 1411:334-50.
31. Humbert P, Niroomand F, Fischer G, Mayer B, Koesling D, Hinsch KID, et al. Purification of soluble guanylyl cyclase from bovine lung by a new immunoaffinity chromatographic method. Eur J Biochem 1990; 190:273-8.
32. MuIsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, Busse R. Effect of YC-1, an NO-independent, superoxioe-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol, 1997; 120:681-9.
33. Nakane M, Hsieh G, Miller LN, Chang R, Terranova MA, Moreland RB, et al. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int J Impot Res 2002; 14:121-7.
34. Lee YC, Martin E, Murad F. Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. Proc Natl Acad Sci USA, 2000; 97:10763-8.
35. Friebe A, Russwurm M, Mergia E, Koesling D. A point-mutated guanylyl cyclase with features of the YC-1-stimulated enzyme: implications for the YC-1 binding site? Biochemistry 1999; 38:15253-7.
36. Miller LN, Nakane M, Hsieh GC, Chang R, Kolasa T, Moreland RB, et al. A-350619: a novel activator of soluble guanylyl cyclase. Life Sci 2003; 72:1015-25.
37. Galle J, Zabel U, Hubner U, Hatzelmann A,Wagner B, Wanner C, et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 1999; 127:195-203.
38. Hwang TL, Wu CC, Teng CM. YC-1 potentiates nitric oxide-induced relaxation in guinea-pig trachea. Br J Pharmacol 1999; 128:577-84.
39. Bush PA, Aronson WJ, Buga GM, Rajfer J, Ignarro LJ. Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum. J Urol 1992; 147:1650-5.
40. Holmquist F, Fridstrand M, Hedlund H, Andersson KE. Actions of 3-morpholinosydnonimin (SIN-1) on rabbit isolated penile erectile tissue. J Urol 1993; 150:1310-5.
41. Hsieh GC, O'Neill AB, Moreland RB, Sullivan JP, Brioni JD. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur J Pharmacol 2003; 458:183-9.
42. Wegener JW, Gath 1, Forstermann U, Nawrath H. Activation of soluble guanylyl cyclase by YC-11 in aortic smooth muscle but not in ventricular myocardium from rat. Br J Pharmacol 1997; 122:1523-9.
43. Schmidt K, Schrammel A, Koesling D, Mayer B. Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase byYC-1 and nitric oxide in endothelial cells. Mol Pharmacol 2001; 59:220-4.
44. O'Reilly DA, McLaughlin BE, Marks GS, Brien JF, Nakatsu K. YC-1 enhances the responsiveness of tolerant vascular smooth muscle to glyceryl trinitrate. Can J Physiol Pharmacol 2001; 79:43-8.
45. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75:191-236.
46. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994; 84:4226-33.
47. Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 1997; 320:161-6.
48. Mizusawa H, Hedlund P, Brioni JD, Sullivan JP, Andersson KE. Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J Urol 2002; 167:2276-81.
49. Rothermund L, Friebe A, Paul M, Koesling D, Kreutz R. Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. Br J Pharmacol 2000; 130:205-8.